SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Tangram Doses First Participant in TGM-148 Phase 1 Trial

Tangram says the first participant has received TGM-148 in a Phase 1 trial evaluating the experimental RNAi drug for bleeding disorders.

Related stories